Compare Novavax Inc (NVAX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs BIO-TECHNE Corp — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while BIO-TECHNE Corp trades at $72.4 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 8.6× Novavax Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TECH | |
|---|---|---|
Market Cap | $1.31B | $11.24B |
Sector | Health | Health |
52-Week High | $11.19 | $72.29 |
52-Week Low | $6.22 | $43.31 |
Enterprise Value | $889.30M | $11.32B |
Dividend Yield | — | 0.44% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
